Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LB2102 |
Synonyms | |
Therapy Description |
LB2102 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting DLL3, which potentially induce toxicity in DLL3-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LB2102 | LB-2102|LB 2102 | LB2102 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting DLL3, which potentially induce toxicity in DLL3-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05680922 | Phase I | LB2102 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |